AcuCort AB is a Sweden-based pharmaceutical company. The company develops oral films ISICORT, which involve chemical substance glucocorticoid dexamethasone that is used for the treatment of acute allergic reactions, as well as for nausea and vomiting during chemotherapy treatments. AcuCort AB operates mostly in Nordic countries.

Employees

Sector

Drug Retailers

Calendar

12/08 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
29/07/26	SEK 0.6400	+0.63%	163,874
28/07/26	SEK 0.6360	+0.95%	39,443
27/07/26	SEK 0.6300	0.00%	145,397
24/07/26	SEK 0.6300	+4.30%	303,208
23/07/26	SEK 0.6040	-4.73%	75,130

End-of-day quote SPOTLIGHT STOCK MARKET AB

More quotes

Income Statement and Estimates

More financial data

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

End-of-day quote SPOTLIGHT STOCK MARKET AB Other stock markets 29/07/2026			5-day change	1st Jan Change
0.6400 ^SEK	+0.63%		+0.95%	+6.67%

27/07	AcuCort Receives Renewed FDA Small Business Waiver Ahead of Planned NDA Submission	CI
27/07	AcuCort Renews US FDA Small Business Waiver for New Drug Applications	MT

Market Cap	150M 15.43M 13.56M 12.65M 11.61M 21.74M 1.48B 22.27M 58.68M 731M 57.92M 56.66M 2.53B	P/E 2024	-3.61x	P/E 2025	-5x
Enterprise Value	123M 12.65M 11.12M 10.38M 9.52M 17.82M 1.21B 18.26M 48.11M 600M 47.49M 46.46M 2.07B	EV / Sales 2024	11.3x	EV / Sales 2025	17x
Free-Float	36.58%	Yield 2024 *	-	Yield 2025	-

27/07	AcuCort Receives Renewed FDA Small Business Waiver Ahead of Planned NDA Submission	CI
27/07	AcuCort Renews US FDA Small Business Waiver for New Drug Applications	MT
27/07	FDA waives application fee for Acucort	FW
11/06	Acucort sees increased partner interest ahead of BIO Convention in the U.S.	FW
27/05	AcuCort CEO: Focus on strengthening presence in existing markets, developing new partnerships, and advancing in the US	FW
28/04	Acucort reports slight increase in operating loss	FW
28/04	AcuCort AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
13/04	AcuCort and the FDA Agree on iPSP - Important Step Towards US Market Approval	CI
13/04	AcuCort Makes Progress in US Regulatory Process for Zeqmelit	MT
13/04	Acucort plans to apply for U.S. market approval for Zeqmelit in 2026	RE
13/04	Acucort reaches milestone for US approval of Zeqmelit	FW
20/02	Acucort Reports Expected Minor Earnings Changes – CEO: Glenmark Deal Marks Start of New Phase	FW
20/02	AcuCort AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI

27/07	AcuCort : granted renewed FDA Small Business Waiver – Important milestone ahead of planned NDA submission in 2026	PU
27/07	AcuCort: AcuCort granted renewed FDA Small Business Waiver – Important milestone ahead of planned NDA submission in 2026	PU
27/07	AcuCort granted renewed FDA Small Business Waiver - Important milestone ahead of planned NDA submission in 2026	AQ
17/06	AcuCort: AcuCort publishes newsletter with CEO update	PU
17/06	AcuCort publishes newsletter with CEO update	AQ

AcuCort AB Stock

Stocks

ACUC

SE0009695927

Drug Retailers

Valuation: AcuCort AB

Chart: AcuCort AB

Latest news : AcuCort AB

Press Releases: AcuCort AB

Quotes and Performance

Course Extremes

Managers and Directors: AcuCort AB

Other Drug Retailers

Financials

Company Profile

Quotes

Income Statement and Estimates

1 day	+0.63%
1 week	+0.95%
Current month	+5.26%
1 month	+7.38%
3 months	-9.86%
6 months	-21.28%
Current year	+6.67%

1 week	0.58	0.65
1 month	0.53	0.67
Current year	0.4	0.95
1 year	0.4	0.95
3 years	0.33	1.26
5 years	0.33	4.98
10 years	0.33	9.5

Manager	Title	Age	Since
Jonas Jonas Jönmark CEO	Chief Executive Officer	55	09/08/2020
Anna Cherouvrier Hansson PRN	Corporate Officer/Principal	53	14/10/2025

Director	Title	Age	Since
Anna Maria Albertina Eriksrud BRD	Director/Board Member	68	08/02/2017
Ebba Cecilia Fåhraeus CHM	Chairman	63	01/01/2018
Göran Tornling BRD	Director/Board Member	79	01/01/2021

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ACUCORT AB	+0.63%	+0.95%	-5.88%	-44.83%	15.43M
JD HEALTH INTERNATIONAL INC.	-1.80%	+4.75%	-21.83%	-30.23%	16.27B
ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED	-1.67%	+2.92%	-28.83%	-36.05%	7.4B
MATSUKIYOCOCOKARA & CO.	-2.01%	+7.98%	-15.26%	-4.82%	6.46B
YIFENG PHARMACY CHAIN CO., LTD.	+1.02%	+4.32%	-4.82%	-29.25%	4.06B
NAHDI MEDICAL COMPANY	+0.37%	+4.28%	-22.79%	-45.99%	3.28B
DASHENLIN PHARMACEUTICAL GROUP CO., LTD.	+0.74%	+1.17%	+9.08%	-32.36%	3.19B
CLICKS GROUP LIMITED	0.00%	-1.35%	-41.74%	-23.50%	3.02B
CORPORATIVO FRAGUA, S.A.B. DE C.V.	+2.65%	+7.10%	-9.89%	+5.73%	2.72B
GUARDIAN PHARMACY SERVICES, INC.	+0.29%	+4.59%	+101.42%	-	2.6B
Average	+0.02%	+4.67%	-4.05%	-26.81%	4.9B
Weighted average by Cap.	-0.80%	+5.35%	-12.69%	-26.26%

	2024	2025
Net sales	7.72M 793K 697K 651K 597K 1.12M 76M 1.15M 3.02M 37.61M 2.98M 2.91M 130M	6.68M 687K 604K 564K 517K 968K 65.82M 992K 2.61M 32.57M 2.58M 2.52M 113M
Net income	-17.4M -1.79M -1.57M -1.47M -1.35M -2.52M -171M -2.58M -6.8M -84.79M -6.72M -6.57M -293M	-26.19M -2.69M -2.37M -2.21M -2.03M -3.79M -258M -3.89M -10.24M -128M -10.11M -9.89M -441M
Net Debt	-2.77M -285K -250K -234K -215K -402K -27.3M -411K -1.08M -13.51M -1.07M -1.05M -46.7M	-27.01M -2.78M -2.44M -2.28M -2.09M -3.91M -266M -4.01M -10.56M -132M -10.43M -10.2M -455M